Literature DB >> 17918441

[Assessment of Pueraria lobata isoflavone with self-microemulsifying drug delivery systems in vitro and in vivo].

Sheng-Miao Cui1, Chun-Shun Zhao, Zhong-Gui He.   

Abstract

OBJECTIVE: To evaluate the self-microemulsifying ability and dissolution behavior of pueraria lobata isoflavone in vitro and the pharmacokinetic behavior in rats.
METHODS: The self-microemulsifying rate was evaluated by the self-microemulsifying time and the self-microemulsifying efficiency was evaluated by the particle size of resultant microemulsions. The plasma concentrations were evaluated by HPLC and dissolution and pharmacokinetic behavior of self-microemulsifying drug delivery systems were evaluated by comparison with commercial tablets.
RESULTS: The system was self-microemulsified in 2 min and the particle size was less than 50 nm. The dis- solution of SMESC in distilled water was more than 90% at 10 min, while those of the commercial tablet were less than 50% at 120 min. 82% increase in the relative bioavailability was observed for the self microemulsifying drug delivery systems compared with Yufengningxin tablets. Tmax was smaller in the self-microemulsifying drug delivery systems compared with Yufengningxin tablets.
CONCLUSION: The self-microemulsifying drug delivery systems can increase drug dissolution in vitro and absorption in vivo significantly.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17918441

Source DB:  PubMed          Journal:  Zhong Yao Cai        ISSN: 1001-4454


  2 in total

1.  Comparison among Activities and Isoflavonoids from Pueraria thunbergiana Aerial Parts and Root.

Authors:  Eunjung Son; Jong-Moon Yoon; Bong-Jeun An; Yun Mi Lee; Jimin Cha; Gyeong-Yup Chi; Dong-Seon Kim
Journal:  Molecules       Date:  2019-03-05       Impact factor: 4.411

2.  Protective activity of kudzu (Pueraria thunbergiana) vine on chemically-induced hepatotoxicity: in vitro and in vivo studies.

Authors:  Bo Yoon Chang; Dong-Sung Lee; Jun-Kyoung Lee; Youn-Chul Kim; Hyoung-Kwon Cho; Sung Yeon Kim
Journal:  BMC Complement Altern Med       Date:  2016-01-29       Impact factor: 3.659

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.